Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes

- 69 percent reduction in triglycerides achieved

- 1.22 percent reduction in HbA1c achieved

May 01, 2014, 07:00 ET from Isis Pharmaceuticals, Inc.

$countyNameToPathMap.put("sp